Breast Carcinoma
|
0.390 |
Biomarker
|
disease |
BEFREE |
CD30 and ALK expression was not seen in any of the cases.Our cohort showed complete negativity to both CD30 and ALK, adding to the conflicting data available in the literature, and more studies are needed to reliably identify a trend of expression of CD30 and ALK in breast carcinoma, especially in the Middle East.
|
31393373 |
2019 |
Breast Carcinoma
|
0.390 |
Biomarker
|
disease |
CTD_human |
A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer.
|
29915430 |
2018 |
Breast Carcinoma
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
We aimed to comprehensively study the prevalence of ALK expression, and changes in copy number and translocation in a large cohort of breast cancer cases in a Middle Eastern population.
|
26384210 |
2015 |
Breast Carcinoma
|
0.390 |
Biomarker
|
disease |
BEFREE |
Anaplastic lymphoma kinase (ALK) is correlated with oncogenesis in different types of cancers, such as anaplastic large cell lymphoma, lung cancer, neuroblastoma, and even breast cancer, by abnormal fusion of ALK or non-fusion ALK activation.
|
26529396 |
2015 |
Breast Carcinoma
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
We examined the expression of β III-tubulin, thymidylate synthase, breast cancer susceptibility gene 1 and ribonucleotide reductase M1 (RRM1); identified mutations in epidermal growth factor receptor (EGFR), KRAS, BRAF and HER2; and detected ALK, ROS1 and RET rearrangements.
|
25257380 |
2015 |
Breast Carcinoma
|
0.390 |
Biomarker
|
disease |
BEFREE |
Since ALK amplified breast cancer cells were shown to respond to ALK inhibitors, ALK amplified oesophageal cancers might be considered as possible candidates for therapies targeting ALK.
|
23490651 |
2013 |
Breast Carcinoma
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
The authors of this report investigated the relation of EGFR mutation or ALK rearrangement status and the expression of DNA repair or synthesis genes, including excision repair cross-complementing 1 (ERCC1), ribonucleotide reductase subunit M1 (RRM1), thymidylate synthetase (TS), and breast cancer-early onset (BRCA1), as a potential explanation for these observations.
|
22569898 |
2012 |
Breast Carcinoma
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncology molecular testing: BRAF V600E for vemurafenib in melanoma; EML4-ALK for crizotinib and EGFR for erlotinib and gefitinib in non-small-cell lung cancer; KRAS against the use of cetuximab and panitumumab in colorectal cancer; ERBB2 (HER2/neu) for trastuzumab in breast cancer; BCR-ABL for tyrosine kinase inhibitors in chronic myeloid leukemia; and PML/RARα for all-trans-retinoic acid and arsenic trioxide treatment for acute promyelocytic leukemia.
|
22845480 |
2012 |
Breast Carcinoma
|
0.390 |
Biomarker
|
disease |
BEFREE |
In addition to those cancers for which a causative role for aberrant ALK activity is well validated, more circumstantial links implicate the full-length, normal ALK receptor in the genesis of other malignancies - including glioblastoma and breast cancer - via a mechanism of receptor activation involving autocrine and/or paracrine growth loops with the reported ALK ligands, pleiotrophin and midkine.
|
19275511 |
2009 |
Breast Carcinoma
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
Cell lines established from solid tumors of ectodermal origin, including melanoma and breast carcinoma, exhibited widespread mRNA expression of the ALK receptor at a broad range (53/64), an association which was found to be strongest in cell lines derived from neuroblastoma (6/6), glioblastoma (8/8) as well as in cell lines established from Ewing sarcoma (4/4) and retinoblastomas (2/2).
|
12115586 |
2002 |